Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 4/20 | 0.36 |
| ▸ | ATRIP | Q8WXE1 | 4/20 | 0.36 |
| ▸ | JAK3 | P52333 | 5/20 | 0.35 |
| ▸ | JAK1 | P23458 | 3/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2016056 | 1.00 | OPRM1 (0.41) | OPRM1OPRD1OPRK1OGFRL1SCN9A | |
| SCHEMBL2018827 | 0.74 | BRD4 (0.50) | OPRM1OPRD1OPRK1OGFRL1JAK1 | |
| SCHEMBL2018828 | 0.74 | BRD4 (0.50) | OPRM1OPRD1OPRK1OGFRL1JAK1 | |
| SCHEMBL7752203 | 0.72 | ADORA1 (0.47) | SCN9ASMN1; SMN2GAAMTORJAK3 | |
| SCHEMBL4077312 | 0.70 | ADORA1 (0.47) | OGFRL1SMN1; SMN2GAAMTORJAK3 | |
| SCHEMBL8355465 | 0.70 | ADORA1 (0.47) | OGFRL1SMN1; SMN2GAAMTORJAK3 | |
| SCHEMBL2825572 | 0.70 | ADORA1 (0.47) | OGFRL1SMN1; SMN2GAAMTORJAK3 | |
| SCHEMBL5189246 | 0.70 | ADORA1 (0.47) | OGFRL1SMN1; SMN2GAAMTORJAK3 | |
| SCHEMBL2016368 | 0.69 | PAK4 (0.39) | JAK3JAK1JAK2 | |
| SCHEMBL4170101 | 0.69 | ADORA1 (0.44) | SCN9ASMN1; SMN2GAAMTORJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2011-06-30 | — | — | US | disclosed |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S.A. (ES) | 2010-05-06 | — | — | US | disclosed |
| EP-2142550-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | Palau Pharma, S.A. (ES) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119792-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | PALAU PHARMA, S. A. (ES) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160185-A9 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | OPRM1 3640/4885OPRD1 2119/4885OPRK1 2268/4885 |
| US-20100113420-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS JAK3 INHIBITORS | JAK3, JAK2, JAK1 | OPRM1 3640/4885OPRD1 2119/4885OPRK1 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.